好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Exploring the Temporal Evolution of Structural and Functional Changes after Acute Optic Neuritis
Neuro-ophthalmology/Neuro-otology
S47 - (-)
003
Spectral-Domain OCT (SD-OCT) detects axonal loss [retinal nerve fiber layer (RNFL) thinning] and neuronal degeneration [macular volume (MV) loss] in ON/MS patients. SD-OCT has been proposed as an outcome measure in the "ON Model" of central nervous system (CNS) inflammation.
In this prospective cohort study, 50 ON patients with acute ON underwent serial vision, SD-OCT, and neurological testing within 30 days of symptom onset (baseline), 3-months, 6-months, and 12-months. Descriptive statistics were calculated for patient demo-graphics. For analysis of correlated data, random effects mixed model (mixed effect, maximum likelihood regression) was fitted to account for random effects of patient and follow-up time when determining the relationship between RNFL and VF over time. To test potential predictors of change in RNFL thickness, multiple linear regression model was used.
The mean age of patients was 35.5 years (43 females). Mean RNFL thickness in ON eyes decreased from baseline [102.8 [micro]m] to 3-months [85.3[micro]m] (p < 0.05); from 3-months to 6-months [77.7[micro]m] (p < 0.05); and from 6-months to 12-months [72.1[micro]m] (P < 0.05). Acutely, higher RNFL values corresponded to more severe vision loss, whereas during recovery, higher RNFL measures were associated with better visual function. Male patients on average lost 35[micro]m of RNFL thickness more than female patients (p=0.05). Older patients developed less RNFL loss: at 6-months, an older ON patient could manifest 18um (p=0.015) less RNFL thinning than a patient 10 years younger.
SD-OCT captures RNFL and macular volume changes after acute ON. The impact of gender, age, disease duration and other factors needs to be considered in future trials using OCT as an outcome measure in the ON model of MS.
Authors/Disclosures
Fiona E. Costello, MD (Fiona Costello Professional Corporation)
PRESENTER 		Dr. Costello has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Accure Therapeutics. Dr. Costello has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for the Sumaira Foundation.
Jodie Burton, MD, FAAN Dr. Burton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Burton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Burton has received personal compensation in the range of $0-$499 for serving as a Consultant for Horizon. The institution of Dr. Burton has received research support from Roy and Joan Allen Professorship for Sight. Dr. Burton has a non-compensated relationship as a Advisor with CADTH that is relevant to AAN interests or activities. Dr. Burton has a non-compensated relationship as a Advisor with Alexion that is relevant to AAN interests or activities. Dr. Burton has a non-compensated relationship as a Advisor with Horizon that is relevant to AAN interests or activities. Dr. Burton has a non-compensated relationship as a 好色先生al Chair with EMD Serono that is relevant to AAN interests or activities.
No disclosure on file
No disclosure on file
No disclosure on file
Vladimir S. Kostic, MD, PhD (Institute of Neurology CCS) Dr. Kostic has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Roche. An immediate family member of Dr. Kostic has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Alkaloid. The institution of Dr. Kostic has received research support from Ministry of 好色先生, Science and Technological Development of Serbia.